{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:18:32Z","timestamp":1778876312275,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["R01CA271592"],"award-info":[{"award-number":["R01CA271592"]}]},{"name":"NIH","award":["R01CA231099"],"award-info":[{"award-number":["R01CA231099"]}]},{"name":"University of Missouri-Kansas City, School of Graduate Studies"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11095-026-04046-y","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:33:15Z","timestamp":1771975995000},"page":"1033-1045","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Silencing CD24 Inhibits Proliferation, Migration, and Chemoresistance in Triple-Negative Breast Cancer Cells"],"prefix":"10.1007","volume":"43","author":[{"given":"Yanli","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangfu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"1","key":"4046_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4046_CR2","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s13346-018-0551-3","volume":"8","author":"S Al-Mahmood","year":"2018","unstructured":"Al-Mahmood S, et al. Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res. 2018;8(5):1483\u2013507.","journal-title":"Drug Deliv Transl Res"},{"issue":"Suppl 2","key":"4046_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000504","volume":"4","author":"R Caparica","year":"2019","unstructured":"Caparica R, Lambertini M, de Azambuja E. How i treat metastatic triple-negative breast cancer. ESMO Open. 2019;4(Suppl 2): e000504.","journal-title":"ESMO Open"},{"issue":"16","key":"4046_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015302","volume":"98","author":"BM Chue","year":"2019","unstructured":"Chue BM, La Course BD. Case report of long-term survival with metastatic triple-negative breast carcinoma: treatment possibilities for metastatic disease. Medicine (Baltimore). 2019;98(16): e15302.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"4046_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jncc.2021.06.001","volume":"1","author":"JN Xupeng Bai","year":"2021","unstructured":"Xupeng Bai JN, Beretov J, Graham P, Li Y. Immunotherapy for triple-negative breast cancer: a molecular insight into the microenvironment, treatment, and resistance. J Natl Cancer Center. 2021;1(3):75\u201387.","journal-title":"J Natl Cancer Center"},{"key":"4046_CR6","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3389\/fgene.2019.00560","volume":"10","author":"P Zhang","year":"2019","unstructured":"Zhang P, Zheng P, Liu Y. Amplification of the CD24 gene is an independent predictor for poor prognosis of breast cancer. Front Genet. 2019;10:560.","journal-title":"Front Genet"},{"issue":"1","key":"4046_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000491667","volume":"48","author":"X Jing","year":"2018","unstructured":"Jing X, et al. CD24 is a potential biomarker for prognosis in human breast carcinoma. Cell Physiol Biochem. 2018;48(1):111\u20139.","journal-title":"Cell Physiol Biochem"},{"key":"4046_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12081235","author":"E Panagiotou","year":"2022","unstructured":"Panagiotou E, et al. CD24: a novel target for cancer immunotherapy. J Pers Med. 2022. https:\/\/doi.org\/10.3390\/jpm12081235.","journal-title":"J Pers Med"},{"issue":"3","key":"4046_CR9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ijc.33249","volume":"148","author":"P Altevogt","year":"2021","unstructured":"Altevogt P, et al. Novel insights into the function of CD24: a driving force in cancer. Int J Cancer. 2021;148(3):546\u201359.","journal-title":"Int J Cancer"},{"issue":"10","key":"4046_CR10","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/cns.13714","volume":"27","author":"H Wu","year":"2021","unstructured":"Wu H, et al. Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma. CNS Neurosci Ther. 2021;27(10):1105\u201317.","journal-title":"CNS Neurosci Ther"},{"issue":"23","key":"4046_CR11","doi-asserted-by":"publisher","first-page":"10783","DOI":"10.1158\/0008-5472.CAN-05-0619","volume":"65","author":"P Baumann","year":"2005","unstructured":"Baumann P, et al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 2005;65(23):10783\u201393.","journal-title":"Cancer Res"},{"issue":"22","key":"4046_CR12","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1007\/s00018-012-1055-9","volume":"69","author":"NP Bretz","year":"2012","unstructured":"Bretz NP, et al. CD24 controls Src\/STAT3 activity in human tumors. Cell Mol Life Sci. 2012;69(22):3863\u201379.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"4046_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1349-7006.2009.01370.x","volume":"101","author":"W Wang","year":"2010","unstructured":"Wang W, et al. CD24-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. Cancer Sci. 2010;101(1):112\u20139.","journal-title":"Cancer Sci"},{"issue":"4","key":"4046_CR14","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1158\/0008-5472.CAN-05-3855","volume":"66","author":"SC Smith","year":"2006","unstructured":"Smith SC, et al. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res. 2006;66(4):1917\u201322.","journal-title":"Cancer Res"},{"key":"4046_CR15","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.1038\/ncomms6909","volume":"6","author":"L Wang","year":"2015","unstructured":"Wang L, et al. Intracellular CD24 disrupts the ARF-NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation. Nat Commun. 2015;6:5909.","journal-title":"Nat Commun"},{"issue":"10","key":"4046_CR16","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/1078-0432.CCR-15-1927","volume":"22","author":"W Zhang","year":"2016","unstructured":"Zhang W, et al. Silencing of CD24 enhances the PRIMA-1-induced restoration of mutant p53 in prostate cancer cells. Clin Cancer Res. 2016;22(10):2545\u201354.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"4046_CR17","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.1158\/0008-5472.CAN-17-0367","volume":"77","author":"JE Duex","year":"2017","unstructured":"Duex JE, et al. Nuclear CD24 drives tumor growth and is predictive of poor patient prognosis. Cancer Res. 2017;77(18):4858\u201367.","journal-title":"Cancer Res"},{"issue":"10","key":"4046_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139112","volume":"10","author":"MJ Kwon","year":"2015","unstructured":"Kwon MJ, et al. CD24 overexpression is associated with poor prognosis in luminal A and triple-negative breast cancer. PLoS ONE. 2015;10(10): e0139112.","journal-title":"PLoS ONE"},{"issue":"7769","key":"4046_CR19","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","volume":"572","author":"AA Barkal","year":"2019","unstructured":"Barkal AA, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572(7769):392\u20136.","journal-title":"Nature"},{"issue":"1","key":"4046_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96449-7","volume":"11","author":"HW Huth","year":"2021","unstructured":"Huth HW, et al. Translocation of intracellular CD24 constitutes a triggering event for drug resistance in breast cancer. Sci Rep. 2021;11(1): 17077.","journal-title":"Sci Rep"},{"issue":"2","key":"4046_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nrd2742","volume":"8","author":"KA Whitehead","year":"2009","unstructured":"Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129\u201338.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"4046_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1021\/mp800134q","volume":"6","author":"K Gao","year":"2009","unstructured":"Gao K, Huang L. Nonviral methods for siRNA delivery. Mol Pharm. 2009;6(3):651\u20138.","journal-title":"Mol Pharm"},{"issue":"1","key":"4046_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jconrel.2013.07.033","volume":"172","author":"B Qin","year":"2013","unstructured":"Qin B, et al. Development of cholesteryl peptide micelles for siRNA delivery. J Control Release. 2013;172(1):159\u201368.","journal-title":"J Control Release"},{"issue":"29","key":"4046_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abb0616","volume":"6","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, et al. Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer. Sci Adv. 2020;6(29): eabb0616.","journal-title":"Sci Adv"},{"issue":"5","key":"4046_CR25","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.7150\/thno.53102","volume":"11","author":"Y Li","year":"2021","unstructured":"Li Y, et al. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer. Theranostics. 2021;11(5):2182\u2013200.","journal-title":"Theranostics"},{"issue":"13","key":"4046_CR26","first-page":"1709","volume":"17","author":"XL Jiao","year":"2013","unstructured":"Jiao XL, et al. Downregulation of CD24 inhibits invasive growth, facilitates apoptosis and enhances chemosensitivity in gastric cancer AGS cells. Eur Rev Med Pharmacol Sci. 2013;17(13):1709\u201315.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"13","key":"4046_CR27","first-page":"2394","volume":"19","author":"ZL Ma","year":"2015","unstructured":"Ma ZL, et al. Knockdown of CD24 inhibits proliferation, invasion and sensitizes breast cancer MCF-7 cells to tamoxifen in vitro. Eur Rev Med Pharmacol Sci. 2015;19(13):2394\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"4046_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1610","volume":"8","author":"C Sheridan","year":"2006","unstructured":"Sheridan C, et al. CD44+\/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006;8(5): R59.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"4046_CR29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2174\/1570163814666170818125036","volume":"18","author":"S Eyvazi","year":"2018","unstructured":"Eyvazi S, et al. Involvement of CD24 in multiple cancer related pathways makes it an interesting new target for cancer therapy. Curr Cancer Drug Targets. 2018;18(4):328\u201336.","journal-title":"Curr Cancer Drug Targets"},{"key":"4046_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27123661","author":"C Dewi","year":"2022","unstructured":"Dewi C, et al. Signaling pathways and natural compounds in triple-negative breast cancer cell line. Molecules. 2022. https:\/\/doi.org\/10.3390\/molecules27123661.","journal-title":"Molecules"},{"issue":"1","key":"4046_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1042\/BJ20080639","volume":"415","author":"NE Torbett","year":"2008","unstructured":"Torbett NE, et al. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J. 2008;415(1):97\u2013110.","journal-title":"Biochem J"},{"key":"4046_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173419","volume":"885","author":"SS Messeha","year":"2020","unstructured":"Messeha SS, et al. Rosmarinic acid-induced apoptosis and cell cycle arrest in triple-negative breast cancer cells. Eur J Pharmacol. 2020;885: 173419.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"4046_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12964-023-01315-w","volume":"21","author":"Y Yang","year":"2023","unstructured":"Yang Y, et al. Targeting CD24 as a novel immunotherapy for solid cancers. Cell Commun Signal. 2023;21(1):312.","journal-title":"Cell Commun Signal"},{"issue":"5","key":"4046_CR34","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s12282-020-01098-9","volume":"27","author":"A Alkaraki","year":"2020","unstructured":"Alkaraki A, et al. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and beta-catenin genes. Breast Cancer. 2020;27(5):989\u201398.","journal-title":"Breast Cancer"},{"key":"4046_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212438","author":"A Paramanantham","year":"2021","unstructured":"Paramanantham A, et al. Doxorubicin-resistant TNBC cells exhibit rapid growth with cancer stem cell-like properties and EMT phenotype, which can be transferred to parental cells through autocrine signaling. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222212438.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4046_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/nyas.14377","volume":"1499","author":"M Lopez-Yrigoyen","year":"2021","unstructured":"Lopez-Yrigoyen M, Cassetta L, Pollard JW. Macrophage targeting in cancer. Ann N Y Acad Sci. 2021;1499(1):18\u201341.","journal-title":"Ann N Y Acad Sci"},{"key":"4046_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.610303","volume":"11","author":"V Salemme","year":"2021","unstructured":"Salemme V, et al. The crosstalk between tumor cells and the immune microenvironment in breast cancer: implications for immunotherapy. Front Oncol. 2021;11: 610303.","journal-title":"Front Oncol"},{"issue":"6","key":"4046_CR38","first-page":"2759","volume":"36","author":"K Brautigam","year":"2016","unstructured":"Brautigam K, et al. Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate. Anticancer Res. 2016;36(6):2759\u201366.","journal-title":"Anticancer Res"},{"key":"4046_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00103","volume":"2","author":"MM Burdick","year":"2012","unstructured":"Burdick MM, et al. Expression of E-selectin ligands on circulating tumor cells: cross-regulation with cancer stem cell regulatory pathways? Front Oncol. 2012;2: 103.","journal-title":"Front Oncol"},{"key":"4046_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.680968","volume":"9","author":"Z Li","year":"2021","unstructured":"Li Z, et al. Establishment and characterization of a HER2-positive cell line derived from the pleural effusion of a drug-resistant breast cancer patient. Front Cell Dev Biol. 2021;9: 680968.","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"4046_CR41","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/cells8090957","volume":"8","author":"M Nedeljkovic","year":"2019","unstructured":"Nedeljkovic M, Damjanovic A. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. Cells. 2019;8(9):957.","journal-title":"Cells."},{"issue":"7","key":"4046_CR42","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"CF Thorn","year":"2011","unstructured":"Thorn CF, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440\u20136.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"4046_CR43","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.bbrc.2012.09.067","volume":"427","author":"J Koh","year":"2012","unstructured":"Koh J, et al. Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells. Biochem Biophys Res Commun. 2012;427(2):373\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"4046_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156651","volume":"11","author":"V Modur","year":"2016","unstructured":"Modur V, et al. CD24 expression may play a role as a predictive indicator and a modulator of cisplatin treatment response in head and neck squamous cellular carcinoma. PLoS ONE. 2016;11(6): e0156651.","journal-title":"PLoS ONE"},{"issue":"6","key":"4046_CR45","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41556-020-0507-y","volume":"22","author":"JM Perry","year":"2020","unstructured":"Perry JM, et al. Overcoming Wnt-beta-catenin dependent anticancer therapy resistance in leukaemia stem cells. Nat Cell Biol. 2020;22(6):689\u2013700.","journal-title":"Nat Cell Biol"},{"issue":"11","key":"4046_CR46","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, et al. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21(11):799\u2013820.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4046_CR47","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang X, et al. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther. 2021;6(1):75.","journal-title":"Signal Transduct Target Ther"},{"key":"4046_CR48","doi-asserted-by":"publisher","first-page":"15025","DOI":"10.1038\/npjbcancer.2015.25","volume":"2","author":"CB Williams","year":"2016","unstructured":"Williams CB, Yeh ES, Soloff AC. Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. NPJ Breast Cancer. 2016;2:15025.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"4046_CR49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/cas.14705","volume":"112","author":"Y Ozawa","year":"2021","unstructured":"Ozawa Y, et al. CD24, not CD47, negatively impacts upon response to PD-1\/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50. Cancer Sci. 2021;112(1):72\u201380.","journal-title":"Cancer Sci"},{"issue":"3","key":"4046_CR50","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccr.2007.01.013","volume":"11","author":"M Shipitsin","year":"2007","unstructured":"Shipitsin M, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11(3):259\u201373.","journal-title":"Cancer Cell"},{"issue":"8","key":"4046_CR51","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/pros.23973","volume":"80","author":"W Liu","year":"2020","unstructured":"Liu W, et al. A CD24-p53 axis contributes to African American prostate cancer disparities. Prostate. 2020;80(8):609\u201318.","journal-title":"Prostate"},{"issue":"11","key":"4046_CR52","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1158\/0008-5472.CAN-11-0519","volume":"71","author":"JB Overdevest","year":"2011","unstructured":"Overdevest JB, et al. CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res. 2011;71(11):3802\u201311.","journal-title":"Cancer Res"},{"issue":"51","key":"4046_CR53","doi-asserted-by":"publisher","first-page":"E3588","DOI":"10.1073\/pnas.1113960109","volume":"109","author":"JB Overdevest","year":"2012","unstructured":"Overdevest JB, et al. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc Natl Acad Sci U S A. 2012;109(51):E3588\u201396.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4046_CR54","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3892\/or.2015.4521","volume":"35","author":"Z Pei","year":"2016","unstructured":"Pei Z, et al. CD24 promotes the proliferation and inhibits the apoptosis of cervical cancer cells in vitro. Oncol Rep. 2016;35(3):1593\u2013601.","journal-title":"Oncol Rep"},{"issue":"4","key":"4046_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167117","volume":"1870","author":"X He","year":"2024","unstructured":"He X, et al. Unraveling the role of CD24 in hepatocellular carcinoma: involvement of inactivated Hippo signaling and SOX4-mediated regulation. Biochim Biophys Acta (BBA). 2024;1870(4): 167117.","journal-title":"Biochim Biophys Acta (BBA)"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04046-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04046-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04046-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:02:12Z","timestamp":1778875332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04046-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4046"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04046-y","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}}]}}